Cipla’s stock surged following Citi’s ‘Buy’ rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US approvals like gFlovent and gVentolin, alongside a rebound in its US business. Domestically, Cipla’s performance remains strong, supported by its respiratory portfolio. Citi sees earnings bottoming out and highlights attractive valuations for the Indian market.
Citi bullish on Indian equities, sees Nifty at 28,000 by end-2027
Citi Research projects that India’s benchmark Nifty 50 index could hit 28,000 points by the end of 2027. This forecast is based on strong earnings